April 11 (Reuters) - Swiss drugmaker Novartis AG
has entered into a licensing deal worth up to $1.01
billion with Arvinas ( ARVN ) for the U.S. drug developer's
experimental prostate cancer drug, Arvinas ( ARVN ) said on Thursday.